CN102481411A - 用于给药装置的驱动机构 - Google Patents
用于给药装置的驱动机构 Download PDFInfo
- Publication number
- CN102481411A CN102481411A CN2010800336830A CN201080033683A CN102481411A CN 102481411 A CN102481411 A CN 102481411A CN 2010800336830 A CN2010800336830 A CN 2010800336830A CN 201080033683 A CN201080033683 A CN 201080033683A CN 102481411 A CN102481411 A CN 102481411A
- Authority
- CN
- China
- Prior art keywords
- driver
- groove
- drug delivery
- delivery device
- flexible tab
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000007246 mechanism Effects 0.000 title claims abstract description 52
- 238000012377 drug delivery Methods 0.000 title claims abstract description 45
- 230000000903 blocking effect Effects 0.000 claims abstract description 22
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 12
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 description 51
- 108010011459 Exenatide Proteins 0.000 description 48
- 229960001519 exenatide Drugs 0.000 description 48
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 20
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 19
- QEFRNWWLZKMPFJ-YGVKFDHGSA-N L-methionine S-oxide Chemical compound CS(=O)CC[C@H](N)C(O)=O QEFRNWWLZKMPFJ-YGVKFDHGSA-N 0.000 description 17
- 150000003839 salts Chemical class 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 7
- 229940079593 drug Drugs 0.000 description 4
- 229940088597 hormone Drugs 0.000 description 4
- 239000005556 hormone Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 150000004676 glycans Chemical class 0.000 description 3
- 239000003055 low molecular weight heparin Substances 0.000 description 3
- 229940127215 low-molecular weight heparin Drugs 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229920001282 polysaccharide Polymers 0.000 description 3
- 239000005017 polysaccharide Substances 0.000 description 3
- 208000004476 Acute Coronary Syndrome Diseases 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 102000006771 Gonadotropins Human genes 0.000 description 2
- 108010086677 Gonadotropins Proteins 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- -1 antibody Proteins 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002622 gonadotropin Substances 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 125000001831 (C6-C10) heteroaryl group Chemical group 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 108010037003 Buserelin Proteins 0.000 description 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 1
- 125000000041 C6-C10 aryl group Chemical group 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 108010000437 Deamino Arginine Vasopressin Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102400000932 Gonadoliberin-1 Human genes 0.000 description 1
- 108010069236 Goserelin Proteins 0.000 description 1
- BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 101500026183 Homo sapiens Gonadoliberin-1 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108010000817 Leuprolide Proteins 0.000 description 1
- 108010092217 Long-Acting Insulin Proteins 0.000 description 1
- 229940100066 Long-acting insulin Drugs 0.000 description 1
- 102000009151 Luteinizing Hormone Human genes 0.000 description 1
- 108010073521 Luteinizing Hormone Proteins 0.000 description 1
- 108010021717 Nafarelin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 108010047386 Pituitary Hormones Proteins 0.000 description 1
- 102000006877 Pituitary Hormones Human genes 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 208000010378 Pulmonary Embolism Diseases 0.000 description 1
- 108010026951 Short-Acting Insulin Proteins 0.000 description 1
- 229940123958 Short-acting insulin Drugs 0.000 description 1
- 108010010056 Terlipressin Proteins 0.000 description 1
- 108010050144 Triptorelin Pamoate Proteins 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000002585 base Chemical class 0.000 description 1
- 229960002719 buserelin Drugs 0.000 description 1
- CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000001136 chorion Anatomy 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 229960004281 desmopressin Drugs 0.000 description 1
- NFLWUMRGJYTJIN-NXBWRCJVSA-N desmopressin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSCCC(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(N)=O)=O)CCC(=O)N)C1=CC=CC=C1 NFLWUMRGJYTJIN-NXBWRCJVSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 229960005153 enoxaparin sodium Drugs 0.000 description 1
- 229940028334 follicle stimulating hormone Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960001442 gonadorelin Drugs 0.000 description 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
- 229940094892 gonadotropins Drugs 0.000 description 1
- 229960002913 goserelin Drugs 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 1
- 239000000960 hypophysis hormone Substances 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004026 insulin derivative Substances 0.000 description 1
- GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 description 1
- 229960004338 leuprorelin Drugs 0.000 description 1
- 229940040129 luteinizing hormone Drugs 0.000 description 1
- 238000003754 machining Methods 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- RWHUEXWOYVBUCI-ITQXDASVSA-N nafarelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 RWHUEXWOYVBUCI-ITQXDASVSA-N 0.000 description 1
- 229960002333 nafarelin Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000007391 self-medication Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229960003813 terlipressin Drugs 0.000 description 1
- BENFXAYNYRLAIU-QSVFAHTRSA-N terlipressin Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)CN)CSSC1 BENFXAYNYRLAIU-QSVFAHTRSA-N 0.000 description 1
- CIJQTPFWFXOSEO-NDMITSJXSA-J tetrasodium;(2r,3r,4s)-2-[(2r,3s,4r,5r,6s)-5-acetamido-6-[(1r,2r,3r,4r)-4-[(2r,3s,4r,5r,6r)-5-acetamido-6-[(4r,5r,6r)-2-carboxylato-4,5-dihydroxy-6-[[(1r,3r,4r,5r)-3-hydroxy-4-(sulfonatoamino)-6,8-dioxabicyclo[3.2.1]octan-2-yl]oxy]oxan-3-yl]oxy-2-(hydroxy Chemical compound [Na+].[Na+].[Na+].[Na+].O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1O)NC(C)=O)O[C@@H]1C(C[C@H]([C@@H]([C@H]1O)O)O[C@@H]1[C@@H](CO)O[C@H](OC2C(O[C@@H](OC3[C@@H]([C@@H](NS([O-])(=O)=O)[C@@H]4OC[C@H]3O4)O)[C@H](O)[C@H]2O)C([O-])=O)[C@H](NC(C)=O)[C@H]1C)C([O-])=O)[C@@H]1OC(C([O-])=O)=C[C@H](O)[C@H]1O CIJQTPFWFXOSEO-NDMITSJXSA-J 0.000 description 1
- 230000000542 thalamic effect Effects 0.000 description 1
- 230000009424 thromboembolic effect Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 229960004824 triptorelin Drugs 0.000 description 1
- VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31543—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose piston rod reset means, i.e. means for causing or facilitating retraction of piston rod to its starting position during cartridge change
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/3155—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe
- A61M5/31551—Mechanically operated dose setting member by rotational movement of dose setting member, e.g. during setting or filling of a syringe including axial movement of dose setting member
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31545—Setting modes for dosing
- A61M5/31548—Mechanically operated dose setting member
- A61M5/31556—Accuracy improving means
- A61M5/31558—Accuracy improving means using scaling up or down transmissions, e.g. gearbox
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31573—Accuracy improving means
- A61M5/31575—Accuracy improving means using scaling up or down transmissions, e.g. gearbox
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31576—Constructional features or modes of drive mechanisms for piston rods
- A61M5/31583—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod
- A61M5/31585—Constructional features or modes of drive mechanisms for piston rods based on rotational translation, i.e. movement of piston rod is caused by relative rotation between the user activated actuator and the piston rod performed by axially moving actuator, e.g. an injection button
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2403—Ampoule inserted into the ampoule holder
- A61M2005/2407—Ampoule inserted into the ampoule holder from the rear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2488—Ampoule holder connected to rest of syringe via rotation, e.g. threads or bayonet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
- A61M2005/2485—Ampoule holder connected to rest of syringe
- A61M2005/2492—Ampoule holder connected to rest of syringe via snap connection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
- A61M2205/582—Means for facilitating use, e.g. by people with impaired vision by tactile feedback
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31533—Dosing mechanisms, i.e. setting a dose
- A61M5/31535—Means improving security or handling thereof, e.g. blocking means, means preventing insufficient dosing, means allowing correction of overset dose
- A61M5/31541—Means preventing setting of a dose beyond the amount remaining in the cartridge
Landscapes
- Health & Medical Sciences (AREA)
- Vascular Medicine (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
公开了一种用于给药装置的剂量设定机构。该机构包括外壳(17)和具有外部凹槽(30,31)的内壳(5)。内壳引导驱动器(7,9),该驱动器具有设置在其内的阻挡或锁定构件(11,11′),该阻挡或锁定构件可在剂量传送期间将挠性凸片(21)锁定到所述内壳的内部凹槽中以使所述驱动器沿着所述凹槽的路径从而推杆前进使药筒塞运动。刻度盘套管(3)被设置在外壳和内壳之间并且与内壳可旋转地接合。
Description
技术领域
本申请通常致力于用于给药装置的剂量设定机构。特别地,本申请通常致力于一种包括固定的内壳体的剂量设定机构,所述固定的内壳体具有位于该内壳体内部的驱动器和可滑动的锁定件或阻挡构件,该构件锁定挠性凸片到内壳体中的内部凹槽以使驱动器在配药(注射)期间沿着凹槽的路径行进。
背景技术
笔型给药装置在由没有正式医学培训的人进行定期注射中具有应用。这在具有糖尿病的病人中日益常见,其中自我医疗法能使病人有效管理它们的疾病。基本上存在两种类型的笔型给药装置:可重新设置的装置(即,可重复使用的)和非可重新设置的(即,一次性的)。这些类型的笔型给药装置(这样命名是因为它们经常类似于放大的钢笔)通常包括三个主要元件:(i)药筒部,其包括经常容纳在壳体或保持器中的药筒;(ii)连接到所述药筒部的一端的针头组件;以及(iii)连接到药筒部的另一端的剂量给药部。药筒(经常被称为针药管)典型地包括充满医药(例如,胰岛素)的储存器,位于药筒储存器的一端处的可活动的橡胶类型塞或封堵器,以及具有位于经常颈缩的另一端的可刺穿的橡胶密封。卷曲的环形金属带典型地用来将橡胶密封保持在合适的位置。当药筒壳体典型地由塑料做成时,药筒储存器在过去由玻璃做成。该针头组件典型地是可替换的双头针组件。在注射之前,可替换的双头针组件被附连到药筒组件的一端,设定一剂量,然后施与一剂量。该可移除针头组件可旋拧到或推到(即,卡合)药筒组件的可刺穿的密封端。
剂量给药部或剂量设定机构典型地是钢笔装置的用来设定剂量的部分。在注射期间,包含在剂量设定机构内的推杆压靠药筒的塞或封堵器。该力引起容纳在药筒内部的医药注射穿过附连的针头组件。在注射之后,如大部分的给药装置和/或针头组件厂商和供应者通常推荐的,针头组件被移除和丢弃。不同类型的钢笔给药装置,包括一次性的(即,非可重新设置的)和可重复使用的(即,可重新设置的)类型的,已经经过多年的演化。例如,一次性的钢笔给药装置被作为独立的装置供给。该独立的装置没有可移除的预先充满的药筒。而是,预先充满的药筒可从这些装置中移除和替换,而没有损坏装置本身。因此,该一次性的装置不需具有可重新设置的剂量设定机构。
与典型的一次性的笔型装置相比,典型的可重复使用的钢笔给药装置的特征基本上在于两个主要的可重复使用的部件:药筒保持器和剂量设定机构。在药筒被插入到药筒保持器之后,该药筒保持器被附连到剂量设定机构。使用者运用剂量设定机构选择一剂量。在使用者注射设定剂量之前,可替换的双头针组件被附连到药筒壳体。该针头组件可被旋拧到或推到(即,卡合到)药筒壳体的远端。用这样的方式,安装在针头组件上的双端针头刺穿在药筒的远端处的可刺穿的密封件。在注射之后,该针头组件被移除和丢弃。在药筒中的胰岛素已经被用尽之后,使用者将药筒壳体从剂量设定机构分离。然后使用者可从药筒保持器将空的药筒移除并且将空的药筒替换为新的(加满的)药筒。除了将空的药筒替换为新的药筒之外,使用者必须设法准备用于新的药筒的剂量设定机构:剂量设定机构必须被重新设定到开始或最初的位置。例如,在某些典型的可重新设置的装置中,为了重新设定剂量设定机构,在剂量注射期间在远端方向前进的推杆必须设法被拉回到剂量设定机构中。某些已知的将该推杆拉回到剂量设定机构中到重新开始或初始位置的方法在现有技术中是已知的。仅仅作为一个例子,已知的重新设定机构要求使用者将剂量设定机构的推杆或某一其他部分转回或推回(拉回)。已知的剂量设定机构的重新设定具有某些察觉到的缺点。一个察觉到的缺点是钢笔装置使用者不得不拆开该装置以移除空的药筒或设法重新设定该装置。因而,另一个察觉到的缺点是该装置已经高数量的部件因此该装置从制造和从组装的观点看是典型地复杂的。例如,至于使用者如何必须替换空的药筒和重新设定该装置,某些典型的可重新设置的笔型装置不是直观的。另外,因为这些可重新设置的装置使用大量的构成部件,因此这些可重新设置的装置倾向于较大且笨重的,因此不容易随身带来带去或者便于隐藏。因此,通常需要在可重新设置的给药装置的设计和研发中考虑与重新设定问题有关的这些缺点。该希望的给药装置倾向于减少构成部件的数目以及倾向于减小制造成本同时还使该装置组装和制造起来不太复杂。该希望的装置还倾向于简化使用者重新设定剂量设定机构所要求的步骤同时还使得该装置的尺寸不太复杂且更紧凑。
发明内容
因此,本发明的目的是要提供一种改进的尺寸紧凑的给药装置以及提供一种优选的允许易于重新设定的方法。
该目的是通过如权利要求1中限定的给药装置和通过根据权利要求12的方法得以解决的。
本发明的主要构思提供了一种具有内壳体的给药装置,该内壳体具有与驱动器有关的引导卡合件的至少一个内部凹槽。优选地,内壳体在其外表面上具有与数字套管相互作用的花键。
根据示例性装置,本发明致力于一种具有驱动器锁定特征的给药装置,所述驱动器锁定特征包括药筒保持器,该药筒保持器容纳连接到剂量调定组件的药剂药筒。该药筒包括一塞子或活塞,其在剂量输送期间由推杆动作。剂量调定组件包括外壳和固定的内壳,其中内壳具有沿着内表面的轴线的至少一个内部凹槽。该组件包括位于内壳内的驱动器和接合内部凹槽以在剂量调定期间形成制动器的挠性凸片。在驱动器的内部是阻挡构件,其可在剂量分配期间滑动和锁定挠性凸片在凹槽中以使该驱动器被迫沿着凹槽的路径。挠性凸片可以是驱动器的一部分,优选位于所述驱动器的远端附近,或者其可以是阻挡构件的一部分,或者其可是独立的部件。优选地,设置两个或更多挠性凸片。这些凸片可由任何挠性材料制造,优选使用可在剂量设定期间与内壳中的凹槽形成制动器并且最优选的给使用者提供触觉反馈和听觉反馈的材料。如果挠性凸片被关联到所述锁定构件,该挠性凸片被锁定成与所述凹槽接合以使驱动器在剂量分配期间当在锁定位置时沿着所述凹槽的路径。挠性构件可通过驱动器的孔口接合凹槽并且当在所述锁定位置时,所述凸片通过未对准的驱动器孔口被偏置到凹槽中。在另一个实施例中,该阻挡构件具有一孔口,该孔口在当阻挡构件处于非锁定位置时与挠性凸片对准并且当处于锁定位置时与该挠性凸片不对准。当不对准时,该挠性凸片被锁定在凹槽中。该凹槽可平行于内壳的轴线或其可以是螺旋状的。当该凹槽是平行的时,驱动器在剂量注射期间和当该凹槽是螺旋状的时不会旋转,该驱动器在剂量注射期间沿着凹槽的路径旋转因而限定一传动比。进一步地,本发明还涉及通过给药装置设定和注射一定剂量的药剂的方法,该方法包括使用者保持如上所述的注射装置的剂量给药组件并且在第一方向上旋转所述驱动器以设定剂量的第一步骤。在剂量设定期间,驱动器相对于外壳和内壳旋转并且挠性凸片跨过内部凹槽。一旦所述剂量被设定,使用者推动与驱动器咬合的注射按钮以使得驱动器在第二方向上向远端运动。该动作还使阻挡构件在轴向远端方向上运动到锁定位置以接合挠性凸片使得其非可释放地接合所述内部凹槽。这使得驱动器沿着凹槽的路径,同时在第二方向上向远端运动并且最终将药剂从给药装置排出。另一个实施例是通过具有驱动器锁闭特征的注射装置来设定和注射一定剂量的药剂的方法,其中所述驱动器在剂量设定期间在第一方向上相对于壳体的旋转使得与锁定元件有关的挠性凸片可释放地接合并且越过所述凹槽,引起听得见的卡嗒声。一旦所述剂量被设定,使用者推动注射按钮以注射一设定剂量,其使得所述驱动器在第二方向上前进并且使所述锁定构件在轴向远端方向上运动以使挠性凸片被锁定为与所述凹槽接合。这使得驱动器沿着所述凹槽的路径,最终将药剂从给药装置排出。如果该凹槽是线性的,驱动器的第二方向在远端方向上可是线性的。如果所述凹槽是螺旋状的,驱动器的第二方向在所述远端方向上是可旋转的。在每个所述的实施例中,刻度盘套管被设置在外壳和内壳之间并且与内壳的外部凹槽可旋转地接合。该接合可包括一螺母,其被可旋转地固定到剂量刻度盘套管并且螺纹接合到内壳上的外部凹槽。当设定一剂量时,刻度盘套管相对于外壳和内壳旋转。刻度盘套管在近端方向上从外壳和内壳平移开。锁定或阻挡构件可在剂量设定期间在近端方向上被偏置以使凸片形成一制动器。在剂量注射步骤期间,偏置构件,优选一弹簧,由当使用者推动注射按钮时施加的力克服。优选地,该卡合件具有至少一个挠性臂,其接合内壳中的至少一个凹槽以在剂量设定期间形成制动器。另一替代的实施例提供了一种剂量设定机构,其具有近端驱动器,卡合件和锁定构件。所述近端驱动器位于具有内表面的固定的内壳中。该卡合件被形成在近端驱动器和该内壳的内表面之间,其中卡合件在剂量设定期间与内壳中的至少一个凹槽形成一制动器并且在剂量输送期间与内壳锁定。所述锁定构件可在所述近端驱动器内滑动并且在剂量设定期间接合所述卡合件从而将所述卡合件锁定到所述内壳中的至少一个凹槽中。优选地,剂量设定机构进一步包括位于内壳中的远端驱动器,其具有用于在剂量设定和药物分配期间接合所述近端驱动器的连接器。偏置部件可位于所述近端驱动器和所述连接器之间。通过适当地参照附图阅读以下的详细描述,本发明的各个方面的这些以及其他优点对本领域内的技术人员将是显而易见的。
附图说明
图1示出了可重新设置的给药装置的实施例;
图2示出了所述驱动机构的一个实施例的横截面视图以具体地示出在所述内壳的内表面上的至少一个凹槽的线性形状;
图3示出了所述驱动机构的一个实施例的横截面视图以具体地示出在所述内壳的内表面上的至少一个凹槽的螺旋形状;
图4示出了所述驱动机构的一个实施例的横截面视图,其示出了所述阻挡构件接合两个挠性凸片以将它们锁定到所述内壳的凹槽中;
图5是图4所示的驱动机构的一个实施例的横截面视图的特写,其示出了所述阻挡构件处于非锁定位置并且两个挠性凸片与所述内壳中的凹槽形成一制动器;
图6是图4所示的驱动机构的一个实施例的横截面视图的特写,其示出了所述阻挡构件处于锁定位置并且两个挠性凸片与所述内壳中的凹槽锁定;
图7是本发明的驱动机构的替代实施例的驱动器的透视图,其示出了在剂量设定期间在所述驱动器中突起穿过孔的两个挠性凸片;
图8是在其远端具有与其有关的三个挠性凸片的锁定构件的透视图;
图9是本发明的驱动机构的替代实施例的横截面视图的特写,其示出了锁定构件处于非锁定位置并且两个挠性凸片与所述凹槽形成一制动器;以及
图10是本发明的驱动机构的替代实施例的横截面视图的特写,其示出了锁定构件处于锁定位置并且两个挠性凸片与所述内壳中的凹槽锁定。
具体实施方式
术语“药物”或“医药产品”或“药品”用于本文意指含有至少一种药学活性化合物的药物配制剂,
其中在一实施例中,所述药学活性化合物具有高至1500Da的分子量和/或是肽、蛋白质、多糖、疫苗、DNA、RNA、抗体、酶、抗体、激素或寡核苷酸,或上述药学活性化合物的混合物,
其中在另一实施例中,所述药学活性化合物可用于治疗和/或预防糖尿病或与糖尿病相关的并发症如糖尿病视网膜病变、血栓栓塞病症如深静脉或肺血栓栓塞、急性冠状动脉综合征(ACS)、心绞痛、心肌梗死、癌症、黄斑变性、炎症、枯草热、动脉粥样硬化和/或类风湿性关节炎,
其中在另一实施例中,所述药学活性化合物包括至少一种用于治疗和/或预防糖尿病或与糖尿病相关的并发症如糖尿病视网膜病变的肽,
其中在另一实施例中,所述药学活性化合物包括至少一种人胰岛素或人胰岛素类似物或衍生物,胰高血糖素样肽(GLP-1)或其类似物或衍生物,或exedin-3或exedin-4,或exedin-3或exedin-4的类似物或衍生物。
胰岛素类似物例如是Gly(A21)、Arg(B31)、Arg(B32)人胰岛素;Lys(B3),Glu(B29)人胰岛素;Lys(B28)、Pro(B29)人胰岛素;Asp(B28)人胰岛素;人胰岛素,其中B28位的脯氨酸由Asp、Lys、Leu、Val或Ala替代,并且其中B29位的Lys可以由Pro替代;Ala(B26)人胰岛素;Des(B28-B30)人胰岛素;Des(B27)人胰岛素和Des(B30)人胰岛素。
胰岛素衍生物例如是B29-N-肉豆蔻酰-des(B30)人胰岛素;B29-N-棕榈酰-des(B30)人胰岛素;B29-N-肉豆蔻酰人胰岛素;B29-N-棕榈酰人胰岛素;B28-N-肉豆蔻酰LysB28ProB29人胰岛素;B28-N-棕榈酰-LysB28ProB29人胰岛素;B30-N-肉豆蔻酰-ThrB29LysB30人胰岛素;B30-N-棕榈酰-ThrB29LysB30人胰岛素;B29-N-(N-棕榈酰-Y-谷氨酰)-des(B30)人胰岛素;B29-N-(N-石胆酰-Y-谷氨酰)-des(B30)人胰岛素;B29-N-(ω-羧基十七烷酰)-des(B30)人胰岛素和B29-N-(ω-羧基十七烷酰)人胰岛素。
Exendin-4例如意指Exendin-4(1-39),一种序列为HHis-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Leu-Ser-Lys-Gln-Met-Glu-Glu-Glu-Ala-Val-Arg-Leu-Phe-Ile-Glu-Trp-Leu-Lys-Asn-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2的肽。
Exendin-4衍生物是例如选自下列化合物:
H-(Lys)4-des Pro36,des Pro37Exendin-4(1-39)-NH2,
H-(Lys)5-des Pro36,des Pro37 Exendin-4(1-39)-NH2,
des Pro36[Asp28]Exendin-4(1-39),
des Pro36[IsoAsp28]Exendin-4(1-39),
des Pro36[Met(O)14,Asp28]Exendin-4(1-39),
des Pro36[Met(O)14,IsoAsp28]Exendin-4(1-39),
des Pro36[Trp(O2)25,Asp28]Exendin-4(1-39),
des Pro36[Trp(O2)25,IsoAsp28]Exendin-4(1-39),
des Pro36[Met(O)14 Trp(O2)25,Asp28]Exendin-4(1-39),
des Pro36[Met(O)14 Trp(O2)25,IsoAsp28]Exendin-4(1-39);或
des Pro36[Asp28]Exendin-4(1-39),
des Pro36[IsoAsp28]Exendin-4(1-39),
des Pro36[Met(O)14,Asp28]Exendin-4(1-39),
des Pro36[Met(O)14,IsoAsp28]Exendin-4(1-39),
des Pro36[Trp(O2)25,Asp28]Exendin-4(1-39),
des Pro36[Trp(O2)25,IsoAsp28]Exendin-4(1-39),
des Pro36[Met(O)14 Trp(O2)25,Asp28]Exendin-4(1-39),
des Pro36[Met(O)14 Trp(O2)25,IsoAsp28]Exendin-4(1-39),
其中所述基团-Lys6-NH2可以结合至Exendin-4衍生物的C-端;
或具有如下序列的Exendin-4衍生物
H-(Lys)6-des Pro36[Asp28]Exendin-4(1-39)-Lys6-NH2,
des Asp28 Pro36,Pro37,Pro38Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36,Pro38[Asp28]Exendin-4(1-39)-NH2,
H-Asn-(Glu)5des Pro36,Pro37,Pro38[Asp28]Exendin-4(1-39)-NH2,
des Pro36,Pro37,Pro38[Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38[Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36[Trp(O2)25,Asp28]Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36,Pro37,Pro38[Trp(O2)25]Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Trp(O2)25,Asp28]Exendin-4(1-39)-NH2,
des Pro36,Pro37,Pro38[Trp(O2)25,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38 [Trp(O2)25,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Trp(O2)25,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36 [Met(O)14,Asp28]Exendin-4(1-39)-Lys6-NH2
des Met(O)14 Asp28 Pro36,Pro37,Pro38 Exendin-4(1-39)-NH2,
H-(Lys)6-desPro36,Pro37,Pro38[Met(O)14,Asp28]Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Met(O)14,Asp28]Exendin-4(1-39)-NH2,
des Pro36,Pro37,Pro38 [Met(O)14,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38 [Met(O)14,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-Asn-(Glu)5 des Pro36,Pro37,Pro38 [Met(O)14,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-Lys6-des Pro36 [Met(O)14,Trp(O2)25,Asp28]Exendin-4(1-39)-Lys6-NH2,
H-des Asp28 Pro36,Pro37,Pro38 [Met(O)14,Trp(O2)25]Exendin-4(1-39)-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38 [Met(O)14,Asp28]Exendin-4(1-39)-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Met(O)14,Trp(O2)25,Asp28]Exendin-4(1-39)-NH2,
des Pro36,Pro37,Pro38 [Met(O)14,Trp(O2)25,Asp28]Exendin-4(1-39)-(Lys)6-NH2,
H-(Lys)6-des Pro36,Pro37,Pro38 [Met(O)14,Trp(O2)25,Asp28]Exendin-4(S1-39)-(Lys)6-NH2,
H-Asn-(Glu)5-des Pro36,Pro37,Pro38 [Met(O)14,Trp(O2)25,Asp28]Exendin-4(1-39)-(Lys)6-NH2;
或前述Exedin-4衍生物中任一种的药学上可接受的盐或溶剂合物。
激素例如是垂体激素类或丘脑激素类或调节性活性肽及它们的拮抗剂,如Rote Liste,2008版,第50章中所列,如促性腺激素(促卵泡激素、促黄体素、绒毛膜促性腺激素、促配子成熟激素),生长激素(促生长素),去氨加压素,特利加压素,戈那瑞林,曲普瑞林,亮丙瑞林,布舍瑞林,那法瑞林,戈舍瑞林。
多糖例如是葡糖胺聚糖、透明质酸、肝素、低分子量肝素或超低分子量肝素或它们的衍生物,或上述多糖的硫酸化形式,例如,多聚硫酸化形式,和/或它们药学上可接受的盐。多聚硫酸化低分子量肝素的药学上可接受的盐的实例是依诺肝素钠。
药学上可接受的盐例如是酸加成盐和碱式盐。酸加成盐是例如HCl或HBr的盐。碱式盐是例如具有选自碱或碱性物质的阳离子的盐,所述阳离子例如Na+,或K+,或Ca2+,或铵离子N+(R1)(R2)(R3)(R4),其中R1至R4彼此独立地意指:氢,任选地取代的C1-C6-烷基,任选地取代的C2-C6-烯基,任选地取代的C6-C10-芳基,或任选地取代的C6-C10-杂芳基。药学上可接受的盐的其他实例在″雷明顿制药科学″17.编辑Alfonso R.Gennaro(Ed.),马克出版公司,伊斯顿,宾夕法尼亚州,美国,1985中和制药技术百科全书中描述。
药学上可接受溶剂合物是例如水合物。参照图1,示出了根据示例性结构的给药装置1。给药装置1包括一壳体,其具有第一药筒保持部分2,以及剂量设定机构4。给药装置是可重新设置的给药装置(即,可再次使用的装置)或替代地是非可重新设置的给药装置(即,非可再次使用的装置)。药筒保持部分2的第一端和剂量设定机构4的第二端通过连接特征被固定在一起。对于非可重新设置的装置,这些连接特征会是永久的并且非可逆的。对于可重新设置的装置,这些连接特征会是可释放的。在所示出的结构中,药筒壳体2被固定在剂量设定机构4的第二端内。可移除的帽(非示出)被可释放地保持在药筒保持部分或药筒壳体的第二端或远端之上。剂量设定机构4包括剂量刻度盘手柄12和窗或透镜14。剂量标度配置可通过窗或透镜14看到。为了设定容纳在给药装置1内的一定剂量的医物,使用者旋转剂量刻度盘手柄12以使调定剂量通过剂量标度配置在窗或透镜14中是可看到的。图1示出了罩盖从给药装置1的远端18移除的给药装置1。该移除使药筒壳体6暴露。优选地,大量剂量的医药制品可从其分配的药筒(没有示出)被设置在药筒壳体6中。优选地,药筒容纳一种类型药剂,其可以是相对经常的,例如一天一次或一天多次施与的药剂。一个这样的药剂是长效或短效的胰岛素或胰岛素类似物。药筒包括塞或止动器,其保持在药筒的第二端或近端附近。该给药装置还包括驱动器7,优选具有至少两个部分7和9(参见图4);和推杆10(参见图参见图9),其与驱动器9的远端部分15螺纹接合。药筒壳体6具有远端和近端。优选地,药筒壳体6的远端包括用于附连可移除的针头组件的轮毂8。然而,还可以使用其它的针头组件连接机构。如果给药装置1包括可重新设置的装置,该药筒近端被可移除地连接到剂量设定机构4。在一个优选的实施例中,药筒壳体近端经由卡口连接被可移除地连接到剂量设定机构4。然而,如本领域内的技术人员将认识到的,也可以使用其它类型的可移除连接方法,例如螺纹,部分螺纹,坡道和制动器,卡扣锁,搭扣,以及鲁尔锁。如前所述,图1所示的给药装置1的剂量设定机构4可被用作可重复使用的给药装置(即,可被重新设定的给药装置)。在给药装置1包括可重复使用的给药装置的情况下,药筒是可从药筒壳体6移除的。仅通过让使用者将剂量设定机构4从药筒壳体6断开,该药筒可从所述装置1被移除,而没有损坏装置1。在使用中,一旦帽(未示出)被移除,使用者可将合适的针头组件附连到设置在药筒壳体6的远端处的轮毂8。该针头组件可以,例如,被旋拧到壳体6的远端上或替代地可被卡扣到该远端上。在使用之后,该可替换的帽可用来重新盖住药筒壳体6。优选地,可替换的帽的外部尺寸与剂量设定机构4的相似或完全相同以便当可替换的帽在不使用所述装置时处于盖住药筒壳体6的位置之时提供一整体的感觉。图4示出了剂量设定机构的一个结构的透视截面视图。本领域内的技术人员将认识到剂量设定机构4可包括用于可释放地连接到如图1所示的药筒保持器6的药筒保持器的连接机构。然而,如本领域内的技术人员认识到的,剂量设定机构还可包括用于永久地连接到药筒保持器的永久连接机构。剂量设定机构4包括容纳数字(或剂量刻度)套管3的外壳17,固定的内壳5,连接器19,近端驱动器部分7,远端驱动器部分9,以及偏置构件,优选压缩弹簧13。推杆10(参见图10)可接合远端驱动器9内的螺纹15并且被连接到邻接药筒塞20的压板16。在一个结构中,该推杆通常可以是圆形的横截面,然而也可以使用其它的结构和形状。近端和远端驱动器部分位于固定的内壳5内。该内壳在其内表面上具有至少一个凹槽,最优选沿着内壳的轴线设置的一系列或一组凹槽。图2和3表示用于所述凹槽,即线性凹槽30(图2)和螺旋凹槽31(图3)的两个优选的设计。回到图5,6,近端驱动器7具有相关的挠性凸片21。在所示的实施例中,在阻挡构件11中存在两个挠性凸片和两个相应的孔口23,其允许挠性凸片弯曲与壳体5上的凹槽形成一制动器。该制动器或卡合件给使用者提供了当设定一剂量时的听觉和触觉反馈,这是因为当驱动器7与刻度盘套管3外旋(近端地)时,挠性凸片越过该凹槽。这示出在图5中。图4和6表示了阻挡构件11处于其锁定位置,在剂量输送期间向前向远端推动,因而将挠性凸片21锁定到内壳的凹槽中并且保证驱动器沿着所述凹槽的路径。在剂量传送期间,阻挡构件11被向远端推动或滑动压缩偏置部件13,其在剂量设定期间将阻挡构件向近端偏置防止挠性凸片与所述凹槽锁定。锁定构件在剂量传送期间的向远端的滑动限制了挠性凸片21以使近端驱动器部分7被锁定到内壳,确保近端驱动器7在内壳5中沿着所述凹槽的路径。锁定构件11的轴向运动还使得连接器19将远端的驱动器部分9锁定到近端的驱动器部分7以确保驱动器的远端部分在与所述近端驱动器相同的方向上运动。连接器19可作为分离的部件被固定到远端驱动器9或可以是在远端驱动器的模制或机加工期间形成的远端驱动器的一体部分。该连接器在剂量设定和剂量传送期间相对于近端驱动器处于一连接位置并且当该装置被设计成可重新设置的时在优选实施例中处于非连接的位置,正如下面更详细描述的那样。远端部分和近端驱动器部分9和7优选通常是圆柱形的。在替代的实施例中,如图7-10所示,挠性凸片关联于锁定构件11′,优选它们被集成到锁定构件的远端。替代地,所述挠性凸片可以是分离部件的一部分。图9表示锁定构件11′在剂量设定期间处于非锁定的近端位置,其中挠性凸片21充当一制动器,该制动器在当所述驱动器和所述锁定构件外旋时移动进出于所述内部主体5的凹槽。图10表示锁定构件11′处于锁定位置,这发生在当使用者推动注射按钮且向前(向远端)推动所述锁定构件时。该向前的滑动使得凸片被锁定到凹槽中,因为所述驱动器的外表面充当阻挡表面,防止在剂量传送期间凸片脱离凹槽。在正常使用中,剂量设定机构4的操作发生如下。为了调定图4-6所示的结构中的剂量,使用者旋转剂量刻度盘手柄12。近端驱动器7,远端驱动器9,连接器19,偏置元件13和数字套管3与剂量刻度盘手柄12一起旋转。数字套管3在近端方向上远离壳体17延伸。用这样的方式,远端驱动器9的螺纹15在推杆10之上旋转。在运行的极限位置处,数字套管3上的径向止动件接合设置在外壳17或内壳5上的止动件以防止进一步的运动。该推杆的旋转被防止,这是因为远端驱动器的螺纹15具有和内壳5的外部的螺旋凹槽相同的螺距。键连接到内壳5的剂量限制器22可被包括在优选的实施例中并且通过旋转远端驱动器9沿着远端驱动器的螺纹23前进。当驱动器在第一方向(近端)旋转时,挠性凸片21越过形成一制动器的内壳的凹槽30或31。当希望的剂量已经被调定时,然后使用者可通过压下刻度盘手柄12的近端面来分配希望的剂量。当使用者压下所述刻度盘手柄12时,这使一离合器(未示出)位移,其确保剂量刻度盘套管和近端驱动器在剂量设定期间轴向地相对于数字套管3一起运动,使得离合器脱离。一旦所述离合器脱离,锁定构件将被向前驱动以将挠性凸片21锁定到内壳的凹槽30或31中,使得近端驱动器沿着所述凹槽的路径。如果所述凹槽是线性的(笔直的),如图2所示,近端驱动器不会相对于内壳旋转。如果所述凹槽是螺旋状的,如图3所示,近端驱动器将相对于内壳旋转。剂量刻度盘套管3和刻度盘手柄12自由地旋转回到起动位置,而不管所述近端驱动器的运动如何。因为近端驱动器7通过连接器19与远端驱动器9接合,因此所述远端驱动器将沿着与所述近端驱动器相同的路径在相同的方向上运动。当内壳中的凹槽是笔直的且平行于所述内壳的轴线时,防止所述驱动器相对于主壳体17和内壳5旋转,但是所述驱动器将轴向地旋转和运动,如果所述凹槽是螺旋状的话。在任一情况下,驱动器的纵向的轴向运动使得推杆10旋转从而使得活塞或塞子20在药筒中前进以通过可释放地连接到药筒保持器6的远端8的附连的针头组件排出所述调定剂量的药物。因而,螺旋凹槽31的螺距限定了一传动比,允许增加或减小相对于所述数字套管3的运动距离的推杆10的运动距离。在优选的实施例中,在给药装置已经分配了容纳在药筒中的所有医药之后,使用者会希望将药筒保持器6中的药筒替换为新药筒。然后使用者还必须重新设定剂量设定机构4:例如,然后使用者必须拉回或推动推杆回到剂量设定机构4中。为了拉回如图4-6所示的结构的推杆,驱动器的远端部分和近端部分必须彼此脱开。使用者可推动推杆10,其反过来在近端方向方向上促动驱动器的远端部分压缩偏置部件13,从而将连接器19从所述驱动器的近端部分脱离。在脱开之后,远端的驱动器部分将相对于近端部分自由旋转。在装置重新设定步骤期间,旋转驱动器的远端部分实现了至少两个结果。第一,由于所述驱动器的远端部分旋转,其将推杆相对于剂量4的轴向位置重新设定到完全拉回的位置。第二,旋转驱动器的远端部分还将剂量限制器22轴向地运动或重新设定到最初的或开始位置,因为该剂量限制器被螺纹啮合到所述远端驱动器的外螺纹23并且键连接到所述内壳的内表面上的凹槽中。在该配置中,该剂量限制器22被阻止旋转但将沿着远端驱动器部分9的外螺纹23运动,因为该部分在重新设定步骤期间旋转。图7-10所示的剂量设定机构4的重新设定步骤与关于图4-6所述的相似。已经描述了本发明的示例性的实施例。然而,本领域内的技术人员将理解到,对这些实施例进行的改变和修改没有背离本发明的真实的由权利要求限定的范围和精神。
Claims (15)
1.一种具有驱动器锁定特征的给药装置,包括:
药筒保持器(6),该药筒保持器被配置为容纳连接到剂量调定组件的药筒,其中所述剂量调定组件包括外壳(17)和固定的内壳(5),该内壳在内表面上具有至少一个内部凹槽(30,31);
驱动器(7,9),该驱动器被定位在内壳(5)内;
至少一个挠性凸片(21),该至少一个挠性凸片接合所述内部凹槽(30,31)以在剂量调定期间形成一制动器;以及
阻挡构件(11,11’),该阻挡构件滑动地位于驱动器(7)内并且在剂量分配期间将挠性凸片(21)锁定到凹槽(30,31)中以使所述驱动器沿着所述凹槽的路径。
2.如权利要求1所述的给药装置,其中所述挠性凸片(21)是驱动器(7)的一体部分。
3.如权利要求1或2所述的给药装置,其中阻挡构件(11)具有孔口(23),该孔口在当所述阻挡构件(11)处于非锁定位置时与挠性凸片(21)对准并且当所述阻挡构件处于锁定位置时与挠性凸片(21)未对准。
4.如权利要求1到3中的任一项所述的给药装置,其中所述凹槽(30)平行于所述内壳(5)的轴线。
5.如权利要求1到3中的任一项所述的给药装置,其中所述凹槽(31)沿着所述内壳(5)的轴线是螺旋状的。
6.如权利要求1到5中的任一项所述的给药装置,其中所述锁定构件(11’)被设置有至少一个挠性凸片(21),该至少一个挠性凸片接合内部凹槽(30,31)以在剂量调定期间形成一制动器。
7.如权利要求6所述的给药装置,其中所述驱动器(7)具有接收挠性凸片(21)的孔口。
8.如权利要求6或7所述的给药装置,其中所述孔口在剂量调定期间与挠性凸片(21)对准并且在剂量传送期间与所述挠性凸片未对准。
9.如权利要求1到8中的任一项所述的具有剂量设定机构的给药装置,其中所述剂量设定机构包括:
a.近端驱动器(7),该近端驱动器位于具有内表面的所述固定的内壳(5)内;
b.卡合件(21),该卡合件形成在近端驱动器(7)和所述内壳(5)的内表面之间,其中所述卡合件在剂量设定期间与所述内壳中的至少一个凹槽(30,31)形成一制动器并且在剂量传送期间与所述内壳锁定;以及
c.锁定构件(11,11’),该锁定构件在所述近端驱动器(7)内轴向滑动并且在剂量设定期间接合所述卡合件以将所述卡合件锁定到所述内壳中的至少一个凹槽中。
10.如权利要求9所述的给药装置,进一步包括位于所述内壳(5)内的具有连接器(19)的远端驱动器(9),所述连接器用于在剂量设定和药物分配期间接合近端驱动器(7)。
11.如权利要求9或10所述的给药装置,进一步包括位于近端驱动器(7)和所述连接器(9)之间的偏置构件(13)。
12.一种通过给药装置设定和排出一定剂量的药剂的方法,包括步骤:
保持或提供注射装置的剂量给药组件,其中所述剂量给药组件包括,
外壳(17)和具有至少一个内部凹槽(30,31)的内壳(5);
位于所述内壳内的驱动器(7,9);
接合所述内部凹槽(30,31)以在剂量设定期间形成一制动器的至少一个挠性凸片(21);以及
可滑动地位于所述驱动器内当处于锁定位置时接合挠性凸片(21)的阻挡构件(11,11’);
在剂量设定期间在第一方向上相对于外壳和内壳(17,5)旋转驱动器(7),从而所述挠性凸片跨越所述内部凹槽;
推动联接到所述驱动器(7,9)的注射按钮以引起所述驱动器在第二方向上向远端运动;
使阻挡构件(11,11’)在轴向的远端方向上运动到锁定位置并且接合挠性凸片(21),使得该挠性凸片不可释放地接合所述内部凹槽;以及
将药剂从所述给药装置排出。
13.如权利要求12所述的方法,其中所述内部凹槽(30)沿着所述内壳的轴线是线性的并且所述驱动器的第二方向在远端是线性的。
14.如权利要求12所述的方法,其中所述内部凹槽(30)是螺旋状的并且所述驱动器的第二方向是向远端旋转的。
15.如权利要求12到14之一所述的方法,其中当所述驱动器(7,9)在所述第一方向上旋转时所述挠性凸片(21)产生可听到的卡嗒声并且给使用者提供触觉反馈。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18284209P | 2009-06-01 | 2009-06-01 | |
US61/182,842 | 2009-06-01 | ||
EP09009050 | 2009-07-10 | ||
EP09009050.7 | 2009-07-10 | ||
PCT/EP2010/057481 WO2010139636A1 (en) | 2009-06-01 | 2010-05-28 | A drive mechanism for a drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102481411A true CN102481411A (zh) | 2012-05-30 |
CN102481411B CN102481411B (zh) | 2015-03-18 |
Family
ID=42236351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201080033683.0A Active CN102481411B (zh) | 2009-06-01 | 2010-05-28 | 用于给药装置的驱动机构 |
Country Status (9)
Country | Link |
---|---|
US (2) | US8728043B2 (zh) |
EP (1) | EP2437805B1 (zh) |
JP (1) | JP5674770B2 (zh) |
CN (1) | CN102481411B (zh) |
AU (1) | AU2010255811B2 (zh) |
BR (1) | BRPI1011730A2 (zh) |
CA (1) | CA2762027A1 (zh) |
IL (1) | IL216483A (zh) |
WO (1) | WO2010139636A1 (zh) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003209095A1 (en) | 2002-02-11 | 2003-09-04 | Antares Pharma, Inc. | Intradermal injector |
DK1850892T4 (da) | 2005-01-24 | 2023-06-06 | Antares Pharma Inc | Forfyldt nål-assisteret sprøjtejetinjektor |
US9144648B2 (en) | 2006-05-03 | 2015-09-29 | Antares Pharma, Inc. | Injector with adjustable dosing |
WO2007131013A1 (en) | 2006-05-03 | 2007-11-15 | Antares Pharma, Inc. | Two-stage reconstituting injector |
JP5731829B2 (ja) | 2008-03-10 | 2015-06-10 | アンタレス・ファーマ・インコーポレーテッド | 注射器安全装置 |
CA2732812C (en) | 2008-08-05 | 2017-10-31 | Antares Pharma, Inc. | Multiple dosage injector |
TWI393578B (zh) * | 2009-07-07 | 2013-04-21 | Shl Group Ab | 注射裝置 |
US10232122B2 (en) * | 2009-09-07 | 2019-03-19 | Sanofi-Aventis Deutschland Gmbh | Drive mechanism for drug delivery device |
EP2292286A1 (en) * | 2009-09-07 | 2011-03-09 | Sanofi-Aventis Deutschland GmbH | Drive mechanism for a medication delivery device and medication delivery device |
US9463278B2 (en) * | 2009-09-30 | 2016-10-11 | Sanofi-Aventis Deutschland Gmbh | Resettable drive mechanism for a drug delivery device with guide track and blocking means |
CN102630174B (zh) * | 2009-09-30 | 2014-12-10 | 赛诺菲-安万特德国有限公司 | 用于药物递送装置的驱动机构和用于驱动机构的重置构件 |
TW201127435A (en) * | 2009-09-30 | 2011-08-16 | Sanofi Aventis Deutschland | Drive mechanism for a drug delivery device |
JP5768051B2 (ja) * | 2009-09-30 | 2015-08-26 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 薬物送達デバイス及び薬物送達デバイスのための駆動部材 |
DK2460551T3 (en) * | 2010-12-06 | 2016-08-15 | Sanofi Aventis Deutschland | Drug delivery device with dose knob lock arrangement |
EP2460552A1 (en) * | 2010-12-06 | 2012-06-06 | Sanofi-Aventis Deutschland GmbH | Drug delivery device with locking arrangement for dose button |
GB2486681B (en) | 2010-12-22 | 2017-02-01 | Owen Mumford Ltd | Autoinjectors |
EP2720738B1 (en) * | 2011-06-17 | 2016-01-20 | Sanofi-Aventis Deutschland GmbH | Cartridge holder assembly for drug delivery devices |
US9220660B2 (en) | 2011-07-15 | 2015-12-29 | Antares Pharma, Inc. | Liquid-transfer adapter beveled spike |
US8496619B2 (en) | 2011-07-15 | 2013-07-30 | Antares Pharma, Inc. | Injection device with cammed ram assembly |
KR20150003179A (ko) | 2012-03-06 | 2015-01-08 | 안타레스 팔마, 인코퍼레이티드 | 분리력 특징을 가진 사전충전형 주사기 |
US9950125B2 (en) | 2012-04-06 | 2018-04-24 | Antares Pharma, Inc. | Needle assisted jet injection administration of testosterone compositions |
WO2013169804A1 (en) | 2012-05-07 | 2013-11-14 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
EP2953667B1 (en) | 2013-02-11 | 2019-10-23 | Antares Pharma, Inc. | Needle assisted jet injection device having reduced trigger force |
ES2742046T3 (es) | 2013-03-11 | 2020-02-12 | Antares Pharma Inc | Inyector de dosis con sistema de piñón |
US20230293822A1 (en) * | 2020-06-09 | 2023-09-21 | Sanofi | Drug delivery device and method for determining a dose |
CN116113459A (zh) | 2020-08-04 | 2023-05-12 | 赛诺菲 | 药物递送装置及其模块 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723054A (zh) * | 2002-10-01 | 2006-01-18 | 贝克顿·迪金森公司 | 药物输送笔 |
US20060258988A1 (en) * | 2003-11-03 | 2006-11-16 | Joachim Keitel | Injection device |
CN101528287A (zh) * | 2006-11-03 | 2009-09-09 | 欧文蒙福德有限公司 | 药物输送设备 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3302462A (en) | 1964-05-25 | 1967-02-07 | Dow Chemical Co | Pipetting device with stop mechanism |
DE4112259A1 (de) | 1991-04-15 | 1992-10-22 | Medico Dev Investment Co | Injektionsgeraet |
CA2109087A1 (en) | 1991-04-22 | 1992-10-23 | Nils Goran Helldin | A syringe, including a rod and a piston |
DK175491D0 (da) | 1991-10-18 | 1991-10-18 | Novo Nordisk As | Apparat |
US5423752A (en) | 1992-07-31 | 1995-06-13 | Habley Medical Technology Corporation | Variable proportion dispenser with cartridge replacement assembly |
DE9301334U1 (de) | 1993-02-01 | 1993-04-01 | Ing. Lang & Menke Gmbh, 5870 Hemer | Federscheibe zum Spielausgleich bei Kugellagern |
US5411377A (en) | 1993-03-17 | 1995-05-02 | Houser; Michael P. | Mass displacement wave energy conversion system |
US5584815A (en) | 1993-04-02 | 1996-12-17 | Eli Lilly And Company | Multi-cartridge medication injection device |
DK170604B1 (da) | 1993-12-07 | 1995-11-13 | Niels Erik Holm Aps | Doseringsenhed til dosering af afmålte mængder af en væske |
US5514097A (en) | 1994-02-14 | 1996-05-07 | Genentech, Inc. | Self administered injection pen apparatus and method |
US5792117A (en) | 1994-07-22 | 1998-08-11 | Raya Systems, Inc. | Apparatus for optically determining and electronically recording injection doses in syringes |
AU1860697A (en) | 1995-09-08 | 1997-07-28 | Visionary Medical Products Corporation | Pen-type injector drive mechanism |
US5688251A (en) | 1995-09-19 | 1997-11-18 | Becton Dickinson And Company | Cartridge loading and priming mechanism for a pen injector |
WO1998001172A1 (de) | 1996-07-05 | 1998-01-15 | Disetronic Licensing Ag | Injektionsgerät zum injizieren von flüssigkeit |
EP0996476B1 (en) | 1997-07-14 | 2003-05-21 | Novo Nordisk A/S | Cylinder ampoule |
DE19730999C1 (de) | 1997-07-18 | 1998-12-10 | Disetronic Licensing Ag | Dosierknopfsicherung an einer Vorrichtung zur dosierten Verabreichung eines injizierbaren Produkts |
US5921966A (en) | 1997-08-11 | 1999-07-13 | Becton Dickinson And Company | Medication delivery pen having an improved clutch assembly |
US6096010A (en) | 1998-02-20 | 2000-08-01 | Becton, Dickinson And Company | Repeat-dose medication delivery pen |
US6221053B1 (en) | 1998-02-20 | 2001-04-24 | Becton, Dickinson And Company | Multi-featured medication delivery pen |
DE29818721U1 (de) * | 1998-10-21 | 2000-03-02 | Medico Development Investment Co., Ascona | Injektionsgerät |
ES2258469T3 (es) | 1999-08-05 | 2006-09-01 | Becton Dickinson And Company | Lapiz de administracion de medicacion. |
TW453884B (en) | 1999-09-16 | 2001-09-11 | Novo Nordisk As | Dose setting limiter |
ES2400057T3 (es) | 2001-05-16 | 2013-04-05 | Eli Lilly And Company | Aparato inyector de medicamentos |
ES2236532T3 (es) | 2001-07-16 | 2005-07-16 | Eli Lilly And Company | Aparato de dispensacion de medicamentos configurado para cebarse por rotacion y con traccion/empuje para inyectar funcionalmente. |
AU2003216521A1 (en) | 2002-03-18 | 2003-10-08 | Eli Lilly And Company | Medication dispensing apparatus with gear set for mechanical advantage |
US20040225258A1 (en) | 2002-03-30 | 2004-11-11 | Ernest Balestracci | Tamper evident overcap for a container |
DE10229138B4 (de) | 2002-06-28 | 2008-01-31 | Tecpharma Licensing Ag | Produktausschüttvorrichtung mit Kolbenstangen-Eilrücksetzung |
DE10239784B4 (de) | 2002-08-29 | 2004-12-30 | Tecpharma Licensing Ag | Injektions-, Infusions- oder Inhalationsvorrichtung mit Dosisanzeigevorrichtung |
DE10302163A1 (de) | 2003-01-21 | 2004-07-29 | Tecpharma Licensing Ag | Vorrichtung zur Verabreichung einer vorgebbaren Dosis eines flüssigen Produkts |
US7329241B2 (en) | 2003-02-14 | 2008-02-12 | Valeant Pharmaceuticals North America | Drug delivery system for administering an adjustable preset dose |
GB0304823D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
GB0304822D0 (en) | 2003-03-03 | 2003-04-09 | Dca Internat Ltd | Improvements in and relating to a pen-type injector |
AU2003274797A1 (en) | 2003-03-05 | 2004-09-28 | 3Ip Co., Ltd. | Electronic dart game set and metod of assembling the same |
US20040186437A1 (en) | 2003-03-20 | 2004-09-23 | Frenette Claude E. | Content-coded medical syringe, syringe set and syringe content identification method |
KR101121317B1 (ko) | 2003-08-12 | 2012-03-09 | 일라이 릴리 앤드 캄파니 | 기계적 확대율을 갖는 삼중 나사식 쓰레드를 갖는 약제투여 장치 |
EP1663354A1 (en) | 2003-09-03 | 2006-06-07 | Novo Nordisk A/S | Threaded rod and nut assembly |
DE10351597A1 (de) | 2003-11-05 | 2005-06-16 | Tecpharma Licensing Ag | Vorrichtung für die Verabreichung eines injizierbaren Produkts |
EP1541185A1 (en) | 2003-12-08 | 2005-06-15 | Novo Nordisk A/S | Automatic syringe with priming mechanism |
DK1838367T3 (en) | 2004-09-02 | 2019-03-04 | Sanofi Aventis Deutschland | PROCEDURE FOR COLLECTION OF PHARMACEUTICAL ADMINISTRATION DEVICES |
ATE499130T1 (de) | 2004-12-01 | 2011-03-15 | Novo Nordisk As | Injektionsvorrichtung |
DE102004063648A1 (de) | 2004-12-31 | 2006-07-20 | Tecpharma Licensing Ag | Injektions- oder Infusionsgerät mit Lebensdauer-Ermittlungseinrichtung |
DK1877119T3 (en) | 2005-01-25 | 2018-10-15 | Novo Nordisk As | AN INJECTION DEVICE WITH A DOSAGE END FEEDBACK MECHANISM |
DE102005008280B3 (de) | 2005-02-23 | 2006-07-13 | Tecpharma Licensing Ag | Verabreichungsvorrichtung mit Anzeigetrommel |
DE602006004314D1 (de) | 2005-02-28 | 2009-01-29 | Novo Nordisk As | Dosiseinstellmechanismus für eine injektionsvorrichtung, mit der eine höchstdosis voreingestellt werden kann |
WO2006114395A1 (en) | 2005-04-24 | 2006-11-02 | Novo Nordisk A/S | An injection device with a gearbox |
DE102005022532A1 (de) | 2005-05-17 | 2006-11-23 | Tecpharma Licensing Ag | Verabreichungsvorrichtung mit Zwangs-Priming |
DE102005023824A1 (de) | 2005-05-24 | 2006-12-07 | Tecpharma Licensing Ag | Dosiervorrichtung für eine Injektionsvorrichtung |
DE102005063497B4 (de) | 2005-05-24 | 2009-09-24 | Tecpharma Licensing Ag | Kunststofffeder |
ATE499962T1 (de) | 2005-07-27 | 2011-03-15 | Novo Nordisk As | Dosismechanismus für ein injektionsgerät zur begrenzung einer dosiseinstellung entsprechend der verbleibenden arzneimenge |
US20080269688A1 (en) | 2005-12-08 | 2008-10-30 | Jose Colucci | Dose Indicating Assembly of a Pharmaceutical Injection Device |
DE102005060928A1 (de) | 2005-12-20 | 2007-06-28 | Tecpharma Licensing Ag | Injektionsvorrichtung mit axial überlappendem Dosier- oder Anzeigeglied |
DE102007001432A1 (de) | 2006-08-14 | 2008-02-21 | Tecpharma Licensing Ag | Dosiermechaniksperrung |
DE102006038123C5 (de) | 2006-08-14 | 2012-05-03 | Tecpharma Licensing Ag | Injektionsvorrichtung mit Mechanikverriegelung |
PL3626289T3 (pl) | 2006-09-15 | 2021-06-14 | Ypsomed Ag | Urządzenie wstrzykujące wyposażone w ulepszony element podający |
EP1923084A1 (en) | 2006-11-17 | 2008-05-21 | Sanofi-Aventis Deutschland GmbH | Dosing and drive mechanism for drug delivery device |
US8740857B2 (en) | 2006-12-21 | 2014-06-03 | Novo Nordisk A/S | Syringe device |
EP2125081B1 (en) | 2007-03-23 | 2017-12-20 | Novo Nordisk A/S | An injection device comprising a locking nut |
DE102007019124A1 (de) | 2007-04-23 | 2008-11-06 | Tecpharma Licensing Ag | Rückdrehbare Dosiervorrichtung für eine Injektionsvorrichtung |
DE102007026083A1 (de) | 2007-05-25 | 2008-11-27 | Haselmeier S.A.R.L. | Injektionsgerät |
-
2010
- 2010-05-27 US US12/788,699 patent/US8728043B2/en active Active
- 2010-05-28 BR BRPI1011730A patent/BRPI1011730A2/pt not_active IP Right Cessation
- 2010-05-28 CA CA2762027A patent/CA2762027A1/en not_active Abandoned
- 2010-05-28 US US13/322,347 patent/US9138541B2/en active Active
- 2010-05-28 CN CN201080033683.0A patent/CN102481411B/zh active Active
- 2010-05-28 EP EP10722348.9A patent/EP2437805B1/en active Active
- 2010-05-28 AU AU2010255811A patent/AU2010255811B2/en not_active Ceased
- 2010-05-28 JP JP2012513565A patent/JP5674770B2/ja active Active
- 2010-05-28 WO PCT/EP2010/057481 patent/WO2010139636A1/en active Application Filing
-
2011
- 2011-11-20 IL IL216483A patent/IL216483A/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1723054A (zh) * | 2002-10-01 | 2006-01-18 | 贝克顿·迪金森公司 | 药物输送笔 |
US20060258988A1 (en) * | 2003-11-03 | 2006-11-16 | Joachim Keitel | Injection device |
CN101528287A (zh) * | 2006-11-03 | 2009-09-09 | 欧文蒙福德有限公司 | 药物输送设备 |
Also Published As
Publication number | Publication date |
---|---|
BRPI1011730A2 (pt) | 2016-03-22 |
US20100331806A1 (en) | 2010-12-30 |
EP2437805A1 (en) | 2012-04-11 |
US8728043B2 (en) | 2014-05-20 |
US9138541B2 (en) | 2015-09-22 |
US20120157966A1 (en) | 2012-06-21 |
EP2437805B1 (en) | 2020-03-04 |
JP2012528624A (ja) | 2012-11-15 |
CA2762027A1 (en) | 2010-12-09 |
CN102481411B (zh) | 2015-03-18 |
JP5674770B2 (ja) | 2015-02-25 |
WO2010139636A1 (en) | 2010-12-09 |
AU2010255811A1 (en) | 2011-12-22 |
IL216483A0 (en) | 2012-01-31 |
IL216483A (en) | 2015-06-30 |
AU2010255811B2 (en) | 2014-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102481411B (zh) | 用于给药装置的驱动机构 | |
CN102448516B (zh) | 可复位药物递送装置 | |
CN102448526B (zh) | 用于药物递送装置的复位机构 | |
CN102448518B (zh) | 用于启动药物递送装置的剂量设定机构 | |
CN102458526B (zh) | 用于给药装置的内壳体 | |
CN102458534B (zh) | 具有螺旋形花键的药物递送装置内壳 | |
CN102458530B (zh) | 用于填装药物输送装置的剂量设定机构 | |
CN102630174B (zh) | 用于药物递送装置的驱动机构和用于驱动机构的重置构件 | |
CN102458532B (zh) | 用于给药装置的组件和给药装置 | |
CN102458525A (zh) | 具有可变最大剂量的给药剂量设定机构 | |
HK1168310A (zh) | 用於給藥裝置的驅動機構 | |
HK1168310B (zh) | 用於給藥裝置的驅動機構 | |
HK1167832B (zh) | 可復位藥物遞送裝置 | |
HK1168814B (zh) | 用於藥物遞送裝置的復位機構 | |
HK1168814A (zh) | 用於藥物遞送裝置的復位機構 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant |